Immunohistochemistry analyses demonstrated a significant presence of IDO2 in NSCLC [40], medullary thyroid carcinoma [42], B and T cell lymphomas [50], ovarian cell carcinoma [51], and glioblastoma [52]. This evidence concerns the gene IDO2 and medullary thyroid gland carcinoma.